Analysts Set Expectations for ESPR FY2024 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will post earnings of ($0.27) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.27) per share.

A number of other brokerages also recently issued reports on ESPR. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday. They set a “neutral” rating and a $4.00 price objective on the stock. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Esperion Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $7.30.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $2.17 on Thursday. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The firm has a market cap of $427.57 million, a P/E ratio of -3.39 and a beta of 1.01. The business’s 50 day moving average price is $2.41 and its 200-day moving average price is $2.22.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors have recently modified their holdings of ESPR. Boomfish Wealth Group LLC grew its position in Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 5,102 shares during the last quarter. Summit Financial LLC lifted its position in Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 6,823 shares in the last quarter. National Bank of Canada FI boosted its stake in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Esperion Therapeutics by 45.3% in the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 11,658 shares in the last quarter. Finally, BOKF NA bought a new stake in shares of Esperion Therapeutics in the 2nd quarter worth $26,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.